Great Elm Capital Corp. - 8.125% Notes Due 2029 Stock (NASDAQ: GECCH)

Latest news for Great Elm Capital Corp. - 8.125% Notes Due 2029 (NASDAQ:GECCH) Stock

Great Elm Capital Corp. - 8.125% Notes Due 2029

Truist Securities analyst Robyn Karnauskas maintains Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Buy and raises the price target from $62 to $65.

News

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Bristol-Myers Squibb, Raises Price Target to $65

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) with a Buy and maintains $11 price target.

PSNL

HC Wainwright & Co. Maintains Buy on Personalis, Maintains $11 Price Target

Truist Securities analyst Srikripa Devarakonda maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Buy and lowers the price target from $215 to $211.

ABBV

Truist Securities Maintains Buy on AbbVie, Lowers Price Target to $211

Earnings

Guidance

Health Care

General

ANGO

AngioDynamics Expects 2025 Adjusted EPS Loss Of $0.34 to $0.38 Compared To Prior Guidance Of $0.38-$0.42 And Consensus Of $0.40

Truist Securities analyst Robyn Karnauskas downgrades Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) from Buy to Hold and lowers the price target from $130 to $110.

Downgrades

Truist Securities Downgrades Merck & Co to Hold, Lowers Price Target to $110

Needham analyst Mike Matson maintains Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) with a Buy and maintains $7.25 price target.

Needham Maintains Buy on Personalis, Maintains $7.25 Price Target

B. Riley Securities analyst Mayank Mamtani initiates coverage on Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Buy rating and announces Price Target of $4.

Initiation

NKTR

B. Riley Securities Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $4

<ul>
<li>The Company now expects Med Tech net sales to grow in the range of 12% to 15%, an increase from 10% to 12%</li>
<li>The Company now expects Med Device net sales to be flat, a decrease from 1% to 3%</li>
<li>The Company continues to expect Gross margin to be approximately 52% to 53%</li>
<li>The Company now expects Adjusted EBITDA in the range of $1.0 to $3.0 million, an increase from the previous guidance of a loss of $2.5 million to $0. The updated guidance compares to a pro forma Adjusted EBITDA loss of $3.2 million in fiscal 2024</li>
</ul>

AngioDynamics Continues To Expect 2025 Net Sales Of $282M-$288M, Representing Growth Of Between 4.2%–6.4% Over Fiscal 2024 Pro Forma Revenue Of $270.7M Versus Consensus Of $283.86M

Air Lease Announced That It Delivered 18 New Aircraft From ALC's Orderbook And Sold 14 Aircraft To Third-party Buyers In The Q4 FY24

As of Jan. 8, 2025, two stocks in the financial sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Lesaka Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSAK#NASDAQ">LSAK</a>)</h3>
<ul>
<li>Lesaka Technologies will release second quarter 2025 results after the closing bell on Feb. 5. The company's stock surged around 13% over the past six months and has a <a href="https://www.benzinga.com/quote/LSAK">52-week high of $5.60</a>.</li>
<li>RSI Value: 71.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>LSAK Price Action: Shares of Lesaka Technologies jumped 2.3% to close at $5.27 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Central Plains Bancshares Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPBI#NASDAQ">CPBI</a>)</h3>
<ul>
<li>On Oct. 28, Central Plains Bancshares adopted repurchase program of up to 200,000 shares of its common stock. The company's stock gained around 4% over the past month and <a href="https://www.benzinga.com/quote/CPBI">has a 52-week high</a> of $15.46.</li>
<li>RSI Value: 74.3</li>
<li>CPBI Price Action: Shares of Central Plains Bancshares gained 1.4% to close at $15.00 on Tuesday.</li>
</ul>
Read This Next: 
<ul>
<li>B<a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42846607/bank-of-new-york-mellon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">ank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

CPBI

LSAK

Top 2 Financial Stocks That May Fall Off A Cliff In January

Needham analyst Joseph Stringer maintains Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) with a Buy and maintains $22 price target.

STOK

Needham Maintains Buy on Stoke Therapeutics, Maintains $22 Price Target

Morgan Stanley analyst Alex Poon upgrades NetEase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) from Equal-Weight to Overweight and raises the price target from $90 to $108.

Upgrades

NTES

Morgan Stanley Upgrades NetEase to Overweight, Raises Price Target to $108

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2" rowspan="1">Second Quarter Fiscal 2025 Financial Outlook</td>
</tr>
<tr>
<td colspan="1" rowspan="1">ADS Growth (YoY)</td>
<td colspan="1" rowspan="1">(5.0)% - (3.0)%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Operating Margin1</td>
<td colspan="1" rowspan="1">6.5% - 7.5%</td>
</tr>
</tbody>
</table>
</figure>

MSC Industrial Projects Q2 Fiscal 2025 ADS Decline Of 3%-5% And Operating Margin Of 6.5%-7.5%

<a href="https://www.wsj.com/articles/amd-invests-in-drug-discovery-company-absci-in-push-to-sell-ai-chips-ba9ef2b1?mod=Searchresults_pos1&amp;page=1" title="https://www.wsj.com/articles/amd-invests-in-drug-discovery-company-absci-in-push-to-sell-ai-chips-ba9ef2b1?mod=Searchresults_pos1&amp;page=1">https://www.wsj.com/articles/amd-invests-in-drug-discovery-company-absci-in-push-to-sell-ai-chips-ba9ef2b1?mod=Searchresults_pos1&amp;page=1</a>

ABSI

The Wall Street Journal Reported Advanced Micro Devices Invests $20M n Drug-Discovery Startup Absci

On Monday, Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) announced a major rebranding of its personal computers, aiming to boost sales by adopting a simplified naming strategy similar to Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>).
What Happened: The company has decided to retire long-standing product names like &#8220;XPS&#8221; and &#8220;Inspiron&#8221; in favor of a streamlined approach centered around the Dell name.
The rebranding is part of Dell&#8217;s strategy to make its products more appealing and less confusing for consumers. The new lineup will feature three tiers: Dell, Dell Pro, and Dell Pro Max, echoing Apple&#8217;s naming conventions.
See Also: <a href="https://www.benzinga.com/tech/25/01/42838231/jensen-huang-unveils-3000-personal-ai-supercomputer-the-size-of-a-small-book-it-runs-the-entire-nvidia-ai-stack">Jensen Huang Unveils $3000 ‘Personal AI Supercomputer' The Size Of A Small Book: ‘It Runs The Entire Nvidia AI Stack'</a>
The rebranding is also part of a broader effort to encourage PC upgrades, with AI-optimized systems and the end of support for Microsoft Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Windows 10 as potential catalysts.
Notably, Dell&#8217;s gaming brand, Alienware, will not be affected by the rebranding. The new Dell-branded devices will incorporate neural processing units to improve AI capabilities.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: In November 2024, Dell announced earnings of $2.15 per share for the third quarter, surpassing the analyst consensus estimate of $2.05.
However, the <a href="https://www.benzinga.com/news/earnings/24/11/42201885/dell-technologies-shares-drop-after-q3-revenue-misses-estimates-details">company's quarterly revenue</a> totaled $24.37 billion, falling short of the expected $24.65 billion, though it represented a growth from the $22.25 billion recorded during the same quarter last year.
In the third quarter of 2024, Dell&#8217;s share of global PC shipments dropped to 15.7%, down from 16.7% in the previous quarter. The company remains the third-largest PC vendor worldwide, trailing behind Lenovo and HP, according to Statista.
Price Action: Dell's stock fell by 2.72% on Tuesday, ending the day at $121.27. However, the stock bounced back in Wednesday's pre-market session, increasing by 1.3% to $122.85, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data</a>.
Check out more of Benzinga's Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/25/01/42827345/nvidia-soars-amd-stalls-ai-race-heats-up-at-ces-2025">Nvidia Soars, AMD Stalls: AI Race Heats Up At CES 2025</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Tech

AAPL

DELL

MSFT

Dell Simplifies PC Lineup With Apple-Like Branding: XPS, Inspiron Brands Are Gone For Good

Goldman Sachs analyst Alex Scott upgrades Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) from Sell to Buy and announces $278 price target.

Goldman Sachs Upgrades Travelers Companies to Buy, Announces $278 Price Target

MSC Industrial Direct Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.73 by 17.81 percent. This is a 31.2 percent decrease over earnings of $1.25 per share from the same period last year. The company reported quarterly sales of $928.500 million which beat the analyst consensus estimate of $904.604 million by 2.64 percent. This is a 2.67 percent decrease over sales of $953.969 million the same period last year.

Earnings Beats

MSC Industrial Direct Co Q1 2025 Adj. EPS $0.86 Beats $0.73 Estimate, Sales $928.500M Beat $904.604M Estimate

Needham analyst Gil Blum maintains Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) with a Buy and lowers the price target from $10 to $8.

GBIO

Needham Maintains Buy on Generation Bio, Lowers Price Target to $8

GTLS

Chart Industries Announce Its Signing Of A Global Master Goods And Services Agreement With ExxonMobil

Goldman Sachs analyst Robert Cox downgrades Fidelis Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIHL#NYSE">FIHL</a>) from Neutral to Sell and lowers the price target from $21 to $16.

Comments

Great Elm Capital Corp. - 8.125% Notes Due 2029

News

Latest news for Great Elm Capital Corp. - 8.125% Notes Due 2029 (NASDAQ:GECCH) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga